English, PDF, 108kb
The future of public health: policy decisions today for tomorrow’s populations. Our health, our economy, our society, our future: a Brave New World. Remarks by Yves Leterme, Deputy Secretary-General, OECD. Brussels, Belgium, September 4th 2013.
This report presents the findings of a research project to investigate the drivers and criteria shaping the application of genomic biotechnology to health in different national settings, and the barriers to implementation nationally and internationally. Findings are based on case studies on Finland, Israel, Luxembourg, Mexico, the United Kingdom, China and South Africa.
English, PDF, 1,115kb
Experience from the substantial health gains of the 20th century suggests that spending on prevention could be an important factor. Therefore, gathering data on such spending that are consistent and comparable, both over time and across countries, is potentially very useful. This paper aims to help clarify what should be included as spending on prevention under SHA 2011 to facilitate accurate comparisons.
Belgium has a good record in delivering accessible care, but adaptation to population ageing will be complicated by the fragmentation of responsibilities in the healthcare system and a strong reliance on government regulations.
After falling sharply in 2010, health spending remained flat across OECD countries in 2011 as the economic crisis continued to have an impact, particularly in those European countries hardest hit by the crisis, according to OECD Health Data 2013.
This paper provides new projections of public spending on health and long-term care for OECD countries and the BRIICS countries (Brazil, Russia, India, Indonesia, China and South Africa). Despite the inevitable uncertainty surrounding projections, they suggest a rapidly rising trend over the next 50 years.
Restoring fiscal sustainability is a major challenge in Slovenia. Yet, the performance in terms of expenditure control is poor and public expenditure on social spending increased briskly during the crisis, significantly more than on average across the OECD.
This paper derives estimates of the efficiency of welfare spending in Slovenia and the other OECD countries from data envelopment analysis based on model specifications used in earlier OECD studies.
This paper proposes a new set of public health and long-term care expenditure projections until 2060, seven years after a first set of projections was published by the OECD. It disentangles health from long-term care expenditure, as well as the demographic from the non-demographic drivers, and refines the previous methodology, in particular by extending the country coverage.
The policy study published by the OECD is based on six case studies, an extensive review of the literature, and analysis of relevant data. The report provides context for the analysis of pharmaceutical pricing policies in OECD countries, describes pricing policies employed by the OECD zone and assesses their impact.